Glatiramer Acetate Injection, Solution
Product Images NDC 0378-6960

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Glatiramer Acetate (NDC 0378-6960). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Time To Second Exacerbation (327c5127 6727 4cf8 Acea 838e5f9af458 01)

A Kaplan-Meier curve comparing second exacerbation rates over time for Glatiramer Acetate 20 mg/mL injection versus placebo. The y-axis shows the percentage of second exacerbation, and the x-axis shows days up to 1080. The Glatiramer Acetate group exhibits a consistently lower percentage compared to placebo, with a p-value of 0.0005 and hazard ratio of 0.55.*

FDA Label Image

Figure 2: Median Cumulative Number Of Gd-enhancing Lesions (327c5127 6727 4cf8 Acea 838e5f9af458 02)

A line graph comparing the cumulative median number of enhancing lesions over nine months between Glatiramer Acetate and Placebo groups. The x-axis represents months (0 to 9), and the y-axis shows the cumulative number of lesions from 0 to 18. Two lines represent Glatiramer Acetate in grey, and Placebo in black, with the Placebo group showing a higher cumulative number of lesions over time.*

FDA Label Image

Glatiramer Acetate Injection 20 mg/ml Carton Label (Image 01)

Glatiramer Acetate 20 mg/mL injection solution, subcutaneous use, by Mylan Pharmaceuticals Inc. This carton label includes dosing information of once daily injection, the NDC 0378-6960-93, and indicates the package contains 30 single-dose pre-filled syringes with fixed 1/2 inch 29 gauge needles. Storage instructions recommend refrigeration and protection from light.*

FDA Label Image

Instructions For Use Figure A (Image 02)

Illustration showing components related to Glatiramer Acetate 20 mg/mL subcutaneous injection use. It includes a sharps disposal container, cotton balls, alcohol wipes, an injection diary, and a syringe in blister packaging. These items support safe and hygienic self-administration.*

FDA Label Image

Instructions For Use Figure B (Image 03)

An instructional illustration depicting a person using their hands to insert a syringe into a plastic safety cap or device. The image is labeled as Figure B and appears to be part of step-by-step guidance for preparing or handling an injection device.*

FDA Label Image

Instructions For Use Figure C (Image 04)

An instructional diagram showing recommended subcutaneous injection sites for Glatiramer Acetate injection. It highlights the abdomen (avoiding 2 inches around the belly button), back of hips and arms, upper back portion of the arms, and thighs (about 2 inches above the knee and 2 inches below the groin) as suitable areas for injection.*

FDA Label Image

Instructions For Use Figure D (Image 05)

An instructional illustration labeled 'Figure D' showing a hand pressing a small adhesive patch or dressing onto the skin, likely demonstrating application of a transdermal or injection site dressing.*

FDA Label Image

Instructions For Use Figure E (Image 06)

An instructional diagram consisting of three panels demonstrating how to use a syringe for Glatiramer Acetate injection, solution. The steps show a hand holding and positioning the syringe, with a needle cap being removed before the injection, relevant to the subcutaneous administration of the medication.*

FDA Label Image

Instructions For Use Figure F (Image 07)

An instructional illustration showing a hand pinching an area of skin to prepare for a subcutaneous injection, as depicted in Figure F.*

FDA Label Image

Instructions For Use Figure G (Image 08)

An instructional illustration labeled Figure G showing a hand holding a syringe positioned vertically above the injection site on a bent arm, demonstrating the proper technique for subcutaneous injection of Glatiramer Acetate injection solution.*

FDA Label Image

Instructions For Use Figure H (Image 09)

Instructional illustration labeled Figure H showing a person administering a subcutaneous injection into the abdomen. The image depicts one hand stretching the skin and the other holding a syringe at a right angle, indicating proper injection technique for a subcutaneous route.*

FDA Label Image

Instructions For Use Figure I (Image 10)

An instructional illustration showing a person holding a syringe with one hand while pressing down on a surface with the other hand. An arrow indicates a downward motion, suggesting a step in the preparation or administration of an injection, consistent with subcutaneous injection technique.*

FDA Label Image

Instructions For Use Figure J (Image 11)

An instructional line drawing labeled 'Figure J' showing a hand holding a syringe to administer a subcutaneous injection into the upper arm.*

FDA Label Image

Instructions For Use Figure K (Image 12)

An instructional illustration labeled 'Figure K' showing a hand preparing for a subcutaneous injection, demonstrating finger placement and technique relevant to administering the injection.*

FDA Label Image

Instructions For Use Figure L (Image 13)

Illustration of a medical sharps disposal container with a biohazard symbol on the front, used for safe disposal of injection needles and other sharp medical waste.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.